Clinical bottom line
Gene therapy for inherited retinal diseases (IRDs) is rapidly advancing, offering new hope for patients with previously untreatable vision loss. Recent progress includes improved vector design, genome editing techniques, and delivery methods that enhance safety and efficacy. While several therapies have received regulatory approval, broad application remains limited by genetic heterogeneity and challenges in long-term durability. Comprehensive genetic diagnosis and personalized approaches are essential for optimizing outcomes. Continued innovation in gene editing and nanotechnology holds promise for expanding therapeutic options (Hu et al., 2021; Nuzbrokh et al., 2021; Carvalho et al., 2023).
What the evidence shows
Hu et al. (2021) provide a detailed overview of gene therapy progress in IRDs, highlighting successes such as voretigene neparvovec for RPE65-associated retinal dystrophy. They emphasize advances in adeno-associated virus (AAV) vectors improving retinal cell targeting and expression stability.
Nuzbrokh et al. (2021) discuss translational challenges and clinical trial outcomes, noting that early intervention correlates with better visual function preservation. Their review underscores the importance of precise molecular diagnosis to identify eligible patients.
Carvalho et al. (2023) explore emerging genome editing tools, including CRISPR-Cas systems, and nanotechnology-based delivery platforms that may overcome current vector size limitations and immune responses. These innovations could enable treatment of a wider array of IRD genotypes.
Matczyńska et al. (2024) demonstrate the utility of broad next-generation sequencing (NGS) panels in diagnosing over 1000 patients with inherited eye diseases, facilitating targeted gene therapy candidacy.
DeSouza et al. (2022) review combined stem cell and gene therapy approaches, suggesting potential synergistic benefits for retinal regeneration and functional restoration.
Khan et al. (2023) provide an updated clinical perspective on gene therapy indications, safety profiles, and patient selection criteria, emphasizing multidisciplinary care.
Caveats and uncertainty
Genetic heterogeneity of IRDs complicates development of universal therapies; many mutations remain untargeted.
Long-term safety and durability data are limited, with concerns about immune responses and vector integration.
Delivery methods, such as subretinal injection, carry procedural risks and may limit accessibility.
Cost and infrastructure requirements pose barriers to widespread implementation.
Efficacy may vary depending on disease stage and residual retinal cell viability.
Ethical considerations around genome editing require ongoing evaluation.
How this may change practice
Clinicians should prioritize comprehensive genetic testing to identify candidates for gene therapy and emerging genome editing trials.
Early referral to specialized centers offering gene therapy can optimize timing and outcomes.
Integration of multidisciplinary teams including genetic counselors, retinal specialists, and rehabilitation services is essential.
Awareness of evolving gene therapy indications and safety monitoring protocols will inform patient counseling.
Future practice may incorporate personalized nanotechnology-based delivery systems and combined stem cell-gene therapy strategies.
Ongoing clinical trials and registries will refine patient selection and long-term management guidelines.